Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach

Blood Reviews

Volumn 22, Issue 6, 2008, Pages 293-302

  Lodewyck, Tom ^a   Cornelissen, Jan J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Alternative donors; Non relapse mortality

Indexed keywords

AMSACRINE; ANTILEUKEMIC AGENT; BUSULFAN; CCAAT ENHANCER BINDING PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; NUCLEOPHOSMIN; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR; GENE MUTATION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA REMISSION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE;

DISEASE-FREE SURVIVAL; GRAFT VS LEUKEMIA EFFECT; HUMANS; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 54049147312     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.03.008     Document Type: Article

References (67)

1. Ferrant A., Labopin M., Frassoni F., et al., on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European group for blood and marrow transplantation study. Blood 90 (1997) 2931-2938
2. Slovak M.L., Kopecky K.J., Cassileth P.A., et al., for the Southwest Oncology and the Eastern Cooperative Oncology Group. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96 (2000) 4075-4083
3. Wheatley K., and Gray R. Commentary: Mendelian randomization - an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 33 (2004) 15-17
4. Gray R., and Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 3 (1991) 9-12
5. Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103 (2005) 1652-1658
6. Burnett A.K., Wheatley A.H., Goldstone R.F., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 Trial. Br J Haematol 118 (2002) 385-400
7. Suciu S., Mandelli F., De Witte T., et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients <46 years old with acute myeloid leukemia (AML) in first complete remission (CR1): an intention to treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 102 (2003) 1232-1240
8. Jourdan E., Boiron J.M., Dastague N., et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 23 (2005) 7676-7684
9. Cornelissen J.J., van Putten W.L.J., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
10. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. Erratum in: N Engl J Med. 352:740. N Engl J Med 352 (2005) 254-266
11. Döhner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106 (2005) 3740-3746
12. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106 (2005) 3733-3739
13. Thiede C., Koch S., Creutzig E., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107 (2006) 4011-4020
14. Verhaak R.G.W., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106 (2005) 3747-3754
15. Frohling S., Schlenk R.F., Stolze I., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22 (2004) 624-633
16. Van Waalwijk van Doorn-Khosrovani S., Erpelinck C., et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4 (2003) 31-40
17. Gale R.E., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients excluding acute promyelocytic leukemia from the UK MRC AML10 and 12 trials. Blood 106 (2005) 3658-3665
18. Bornhäuser M., Illmer T., Schaich M., et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML (letter). Blood 109 (2007) 2264
19. Schlenk R.F., Corbacioglu A., Krauter J., et al. Gene mutations as predictive markers for postremission therapy in younger adults with normal karyotype AML. Blood 108 (2006) 6a (abstr)
20. Kern W., Schoch C., Haferlach T., et al. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 56 (2005) 283-309
21. Laane E., Derolf A.S., Björklund E., et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 91 (2006) 833-836
22. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update for the Seattle experience. Bone Marrow Transplant 26 (2000) 397-404
23. Appelbaum F.R. Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. Best Practice & Research Clinical Haematology 20 (2007) 67-75
24. Zuckerman T., and Rowe J.M. Alternative donor transplantation in acute myeloid leukemia: which source and when?. Curr Opin Hematol 14 (2007) 152-161
25. Krauter J., Heil G., Hoelzer D., et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood 106 (2005) 172 abstr
26. Moore J., Nivison-Smith I., Goh K., et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 13 (2007) 601-607
27. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 (2006) 5695-5702
28. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
29. Petersdorf E.W. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 11 (2004) 386-391
30. Lee SJ, Klein J, Haagenson M, et al. High resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Prepublished on September 4, 2007, doi:10.1182/blood-2007-06-097386.
31. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 104 (2004) 1550-1558
32. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
33. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for riks assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
34. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Prepublished on September 14, 2007, as doi:10.1182/blood-2007-06-096966.
35. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (2007) 4246-4254
36. Baron F., and Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol 14 (2007) 145-151
37. Blaise D., Vey N., Faucher C., et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92 (2007) 533-541
38. Martino R., Caballero M.D., Perez Simon J.A., et al., for the AML and alloPBSCT subcommittees of the Spanish Group for Hematopoietic Transplantation (GETH). Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
39. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 (2003) 2021-2030
40. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
41. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110 (2007) 2744-2748
42. Mohty M., De Lavallade H., Ladaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 19 (2005) 916-920
43. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcome of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102 (2003) 2777-2785
44. Hogan W.J., Maris M., Storer B., et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 103 (2004) 78-84
45. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8 (2002) 512-520
46. Diaconsecu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 104 (2004) 1550-1558
47. Martino R, Valcarcel D, Brunet S, et al. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant, prepublished on line 5 November 2007.
48. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
49. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 (2006) 322-328
50. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Keukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
51. Flynn C.M., Hirsch B., Defor T., et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am.J Hematol 82 (2007) 867-872
52. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
53. Alyea E.P., Kim H.T., Ho V., et al. Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation 12 (2006) 1047-1055
54. Parker J.E., Shafi T., Pagliuca A., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. British Journal of Haematology 119 (2002) 144-154
55. Fung H., Stein A., Slovak M., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9 (2003) 766-771
56. Schmid C., Schleuning M., Schwerdtfeger R., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108 (2006) 1092-1099
57. Breems D.A., Van Putten W.L.J., Huijgens P.C., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23 (2005) 1969-1978
58. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adult with acute leukemia. N Engl J Med 351 (2004) 2276-2285
59. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
60. Brunstein C.G., Aker K.S., and Wagner J.E. Umbilical cord blood transplantation for myeloid malignancies. Curr Opin Hematol 14 57 (2007) 162-169
61. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
62. Majhail N.S., Brunstein C.G., and Wagner J.E. Double umbilical cord blood transplantation. Curr Opin Immunol 18 (2006) 571-575
63. Brunstein C.G., Barker N.J., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110 (2007) 3064-3070
64. Chen Y-B, Spitzer TR. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia. Prepublished on September 6, 2007, as doi:10.1038/sj.leu.2404932.
65. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 1-8
66. Aversa R, Reisner Y, Martelli MF. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2007 Sep 28.
67. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 (2007) 433-440